Aldara gets FDA nod for treatment of sBCC.(New Indications)

Publication: Dermatology Times

Bookmark this article Print this article Link to this article Email this article Digg It! Add to del.icio.us RSS

COPYRIGHT 2004 Advanstar Communications, Inc.

St. Paul, Minn. -- Aldara (imiquimod) Cream 5 percent, a topical immune response modifier, has received U.S. Food and Drug Administration (FDA) approval for the treatment of superficial basal cell carcinoma (sBCC).

"The approval of Aldara for superficial basal cell carcinoma, along with the recent actinic keratosis approval, reflects...

Read the full article for free courtesy of your local library.